Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Eric Riss who wrote (997)	3/22/1998 9:24:00 PM
From: luis a. garcia	Respond to of 1115

I know, but a strong partner can be modeled now that I found a very similar stock and with royalties of 30% of sales and 25% global herpes market penetration we can target 35 dollar per share for lidakol.m That assumes a global Lidakol market worth 2 billion. But its tempered by something I read... the global lidakol is expected to bring in 150-200 million so US can match that... lets say 500 million global take, thirty percent of which is 150 million. we will stay tuned for this... The point is if Brystol Myers can do this or a baush and lomb why then deal with a huge loan and dilution and or technology transfers etc...why not just find a new partner...?? regards luis